Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Reimbursement Rare Diseases Commercial

Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage

  • Analysis

Executive Summary

Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.

You may also be interested in...



Quick Commercial Standouts Lacking Among 2016 US Launches

The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.

Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Company plans to meet with caregivers and consider other options before moving forward.

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Scrip
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Reimbursement Rare Diseases Commercial
Latest Headlines

As Japan’s Syphilis Cases Surge, So Do Calls For More Therapeutics

Allorion Rides Unconventional Discovery Platforms To Major Funding

Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout

AbbVie Head-To-Head Data Show Skyrizi Tops IL-17 Competitors In Skin Clearanc

See All
UsernamePublicRestriction

Register

SC098322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By